Literature DB >> 14563459

Musculoskeletal manifestations in cystic fibrosis.

Estelle Botton1, Alain Saraux, Hermine Laselve, Sandrine Jousse, Paul Le Goff.   

Abstract

Although bone and joint manifestations are common in children with cystic fibrosis (CF), they have received little attention in adults. As compared to healthy individuals, bone mineral density is low, even with calcium intakes greater than 1500 mg/d. Nevertheless, calcium and phosphate levels in blood and urine are often normal, and vitamin D levels vary. Short stature with a low body mass index and central hypogonadism are the rule in these patients. Fractures and kyphosis are often reported. CF arthropathy occurs in 2-8.5% of patients. Arthritis develops, and there may be skin eruptions. Non-steroidal antiinflammatory drug therapy is effective. Hypertrophic osteoarthropathy associated with respiratory failure is present in 2-7% of patients. Rheumatoid arthritis, spondyloarthropathies, sarcoidosis, and amyloidosis have been reported in association with CF. Knee pain due to patellofemoral syndrome, quinolone-induced arthropathy, and mechanical back pain have been described. Rheumatoid factor titers are higher than in healthy controls, particularly in patients with episodic arthritis. No data are available on antiperinuclear factor or antikeratin antibody titers. Tests for antinuclear antibody are usually negative. Circulating immune complex levels and antibodies to heat shock proteins may be elevated. Antineutrophil cytoplasmic antibody of the bactericidal/permeability-increasing protein (BPI) or azurocidin (AZ) type has been reported, often in high titers (up to 40%).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14563459     DOI: 10.1016/s1297-319x(03)00063-0

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  14 in total

Review 1.  Pain and its clinical associations in individuals with cystic fibrosis: A systematic review.

Authors:  Annemarie L Lee; Sarah Rawlings; Katharine A Bennett; David Armstrong
Journal:  Chron Respir Dis       Date:  2016-02-12       Impact factor: 2.444

Review 2.  Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy.

Authors:  Sheila Nguyen; Mehrnaz Hojjati
Journal:  Clin Rheumatol       Date:  2010-10-09       Impact factor: 2.980

3.  Developing better biomarkers for connective tissue disease-associated interstitial lung disease: citrullinated hsp90 autoantibodies in rheumatoid arthritis.

Authors:  Kevin D Deane; Mark R Nicolls
Journal:  Arthritis Rheum       Date:  2013-04

Review 4.  When and where does inflammation begin in rheumatoid arthritis?

Authors:  M Kristen Demoruelle; Kevin D Deane; V Michael Holers
Journal:  Curr Opin Rheumatol       Date:  2014-01       Impact factor: 5.006

5.  Lumbar disc herniation in three patients with cystic fibrosis: a case series.

Authors:  Christian Denne; Anna E Vogl-Voswinckel; Harald Wurmser; Marc Steinborn; Manfred Spaeth; Armin Gruebl; Stefan Burdach
Journal:  J Med Case Rep       Date:  2011-09-06

Review 6.  The gut-joint axis in rheumatoid arthritis.

Authors:  Mario M Zaiss; Hsin-Jung Joyce Wu; Daniele Mauro; Georg Schett; Francesco Ciccia
Journal:  Nat Rev Rheumatol       Date:  2021-03-05       Impact factor: 32.286

7.  Physiotherapy for cystic fibrosis in Australia and New Zealand: A clinical practice guideline.

Authors:  Brenda M Button; Christine Wilson; Ruth Dentice; Narelle S Cox; Anna Middleton; Esta Tannenbaum; Jennifer Bishop; Robyn Cobb; Kate Burton; Michelle Wood; Fiona Moran; Ryan Black; Summar Bowen; Rosemary Day; Julie Depiazzi; Katherine Doiron; Michael Doumit; Tiffany Dwyer; Alison Elliot; Louise Fuller; Kathleen Hall; Matthew Hutchins; Melinda Kerr; Annemarie L Lee; Christina Mans; Lauren O'Connor; Ranjana Steward; Angela Potter; Tshepo Rasekaba; Rebecca Scoones; Ben Tarrant; Nathan Ward; Samantha West; Dianne White; Lisa Wilson; Jamie Wood; Anne E Holland
Journal:  Respirology       Date:  2016-04-18       Impact factor: 6.424

8.  The effect of whole body vibration exposure on muscle function in children with cystic fibrosis: a pilot efficacy trial.

Authors:  Kaitlin O'Keefe; Rhonda Orr; Peite Huang; Hiran Selvadurai; Peter Cooper; Craig Frank Munns; Maria A Fiatarone Singh
Journal:  J Clin Med Res       Date:  2013-04-23

9.  Rheumatoid arthritis in a patient with cystic fibrosis: challenging treatment options.

Authors:  Kelly Lynn Delaney-Nelson; Sheena Marie Henry; Chokkalingam Siva
Journal:  BMJ Case Rep       Date:  2020-09-06

10.  Rheumatoid arthritis-associated autoantibodies in non-rheumatoid arthritis patients with mucosal inflammation: a case-control study.

Authors:  Koen M J Janssen; Menke J de Smit; Elisabeth Brouwer; Fenne A C de Kok; Jan Kraan; Josje Altenburg; Marije K Verheul; Leendert A Trouw; Arie Jan van Winkelhoff; Arjan Vissink; Johanna Westra
Journal:  Arthritis Res Ther       Date:  2015-07-09       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.